dc.contributorLlamas-Covarrubias, M.A., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Valle, Y., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Bucala, R., Department of Medicine/Section of Rheumatology, Yale University School of Medicine, New Haven, United States; Navarro-Hern�ndez, R.E., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Palafox-S�nchez, C.A., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Padilla-Guti�rrez, J.R., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Parra-Rojas, I., Unidad Acad�mica de Ciencias Qu�mico Biol�gicas, Universidad Aut�noma de Guerrero, Chilpancingo, Guerrero, Mexico; Bernard-Medina, A.G., Servicio de Reumatolog�a, O.P.D. Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico; Reyes-Castillo, Z., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Mu�oz-Valle, J.F., Functional Immunogenetics Group and PhD Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
dc.creatorLlamas-Covarrubias, M.A.
dc.creatorValle, Y.
dc.creatorBucala, R.
dc.creatorNavarro-Hernandez, R.E.
dc.creatorPalafox-Sanchez, C.A.
dc.creatorPadilla-Gutierrez, J.R.
dc.creatorParra-Rojas, I.
dc.creatorBernard-Medina, A.G.
dc.creatorReyes-Castillo, Z.
dc.creatorMunoz-Valle, J.F.
dc.date.accessioned2015-09-15T18:20:12Z
dc.date.accessioned2022-11-02T16:46:43Z
dc.date.available2015-09-15T18:20:12Z
dc.date.available2022-11-02T16:46:43Z
dc.date.created2015-09-15T18:20:12Z
dc.date.issued2013
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84875373810&partnerID=40&md5=e66d02fc0210ce475e5cd3fdd6384068
dc.identifierhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23402792
dc.identifierhttp://hdl.handle.net/20.500.12104/42633
dc.identifier10.1016/j.cyto.2012.12.032
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5023468
dc.description.abstractMacrophage migration inhibitory factor (MIF) is an upstream pro-inflammatory cytokine that is associated with the pathogenesis of autoimmune inflammatory diseases including rheumatoid arthritis (RA). Two polymorphisms in the upstream region exist in the MIF gene and are associated with RA susceptibility or severity in different populations. In this case-control study, we investigated whether MIF polymorphisms are associated with RA susceptibility or activity in a western Mexican population. The relationship of MIF levels with clinical features of disease also was assessed. Genotyping of the -794 CATT5-8 (rs5844572) and the -173 G>C (rs755622) polymorphisms was performed by PCR and PCR-RFLP respectively on 226 RA patients and 210 healthy subjects. Serum MIF levels were determined by ELISA. We found a significant association between the -794 CATT5-8 6,7 MIF genotype with RA. Moreover, we detected an association between the -794 CATT7 allele with early onset RA. The -794 CATT7 and -173*C alleles, which are in linkage disequilibrium, were associated with high disease activity on RA patients. A positive correlation between circulating MIF levels and C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor, anti-citrullinated protein/peptides antibodies and TNF? was detected. MIF levels appear to be associated with disease progression rather than disease activity, which is distinct from the established relationship between disease activity and TNF? levels. In conclusion, the MIF gene and protein are associated with RA in a western Mexican population, with a main contribution onto early onset and early stages of disease. � 2013 Elsevier Ltd.
dc.relationScopus
dc.relationWOS
dc.relationMEDLINE
dc.relationCytokine
dc.relation61
dc.relation3
dc.relation759
dc.relation765
dc.titleMacrophage migration inhibitory factor (MIF): Genetic evidence for participation in early onset and early stage rheumatoid arthritis
dc.typeArticle


Este ítem pertenece a la siguiente institución